Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cost of Revenue (2017 - 2021)

Historic Cost of Revenue for Neurocrine Biosciences (NBIX) over the last 5 years, with Q3 2021 value amounting to $4.2 million.

  • Neurocrine Biosciences' Cost of Revenue rose 5555.56% to $4.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $12.9 million, marking a year-over-year increase of 3260.69%. This contributed to the annual value of $7.4 million for FY2019, which is 5193.29% up from last year.
  • According to the latest figures from Q3 2021, Neurocrine Biosciences' Cost of Revenue is $4.2 million, which was up 5555.56% from $3.1 million recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Cost of Revenue peaked at $4.2 million during Q3 2021, and registered a low of $61000.0 during Q2 2017.
  • For the 5-year period, Neurocrine Biosciences' Cost of Revenue averaged around $1.8 million, with its median value being $1.6 million (2019).
  • As far as peak fluctuations go, Neurocrine Biosciences' Cost of Revenue surged by 130000.0% in 2018, and later surged by 1578.95% in 2019.
  • Over the past 5 years, Neurocrine Biosciences' Cost of Revenue (Quarter) stood at $760000.0 in 2017, then surged by 101.84% to $1.5 million in 2018, then skyrocketed by 64.8% to $2.5 million in 2019, then increased by 6.8% to $2.7 million in 2020, then skyrocketed by 55.56% to $4.2 million in 2021.
  • Its Cost of Revenue was $4.2 million in Q3 2021, compared to $3.1 million in Q2 2021 and $2.9 million in Q1 2021.